Shares of Shire PLC (ADR) (NASDAQ:SHPG) ended Wednesday session in red amid volatile trading. The shares closed down -0.85 points or -0.44% at $193.60 with 881,469.00 shares getting traded. Post opening the session at $192.00, the shares hit an intraday low of $192.00 and an intraday high of $194.88 and the price vacillated in this range throughout the day. The company has a market cap of $57.89 billion and the numbers of outstanding shares have been calculated to be 906.90 million shares.
On Aug. 29, 2016 Shire plc (SHPG) announced that Xiidra™ (lifitegrast ophthalmic solution) 5%, a twice-daily prescription eye drop indicated for the treatment of both the signs and symptoms of dry eye disease, is now available by prescription in the United States. An estimated 16 million adults in the U.S. are diagnosed with dry eye, a disease associated with inflammation that may eventually lead to damage to the surface of the eye. An eye care professional can diagnose dry eye disease based on signs and symptoms and determine management options, which could include the use of a prescription treatment. The U.S. Food and Drug Administration (FDA) approved Xiidra on July 11, 2016.
“Shire worked rapidly to bring Xiidra to market following the approval of this new treatment – a first-in-its-class medication and the first prescription treatment to be approved for both the signs and symptoms of dry eye disease,” said Perry Sternberg, Head, U.S. Commercial. “We have a full range of modern, educational access programs to support the millions of patients across the U.S. living with dry eye disease. This delivers on our commitment to showing up differently in ophthalmics.”
“As the number of people presenting with the signs and symptoms of dry eye disease increases, the availability of a new prescription treatment option for this condition is an exciting development,” Eric D. Donnenfeld, M.D., FAAO, National Medical Director, TLC Laser Eye Centers. “We now have a new prescription eye drop that is specifically indicated for the signs and symptoms of dry eye disease, an often common eye condition that may be progressive.”
Shares of Amgen, Inc. (NASDAQ:AMGN) ended Wednesday session in red amid volatile trading. The shares closed down -0.21 points or -0.12% at $170.63 with 2.01 million shares getting traded. Post opening the session at $169.78, the shares hit an intraday low of $169.20 and an intraday high of $171.44 and the price vacillated in this range throughout the day. The company has a market cap of $128.50 billion and the numbers of outstanding shares have been calculated to be 748.36 million shares.
Amgen, Inc. (AMGN) on Sept. 7, 2016 announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on Sept. 16-19, 2016. At the congress, Amgen will highlight a diverse set of data across its osteoporosis clinical programs, as well as real-world data that provide important insights on living with osteoporosis and underscore the Company’s commitment to pioneering novel treatment options that can help reduce fracture risk.
“As a leader in bone biology, Amgen is committed to translating innovative science into treatments that make a difference in the lives of people,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “The breadth and depth of clinical and real-world data we’re presenting at ASBMR demonstrates our commitment to finding potential options for patients with osteoporosis. We look forward to sharing detailed data from our Phase 3 FRAME study of romosozumab, along with new clinical data and real-world research on Prolia.”